Altimmune Inc (ALT) USD0.0001

Sell:$3.59Buy:$3.60$0.16 (4.51%)

NASDAQ:0.23%
Market closed |
Prices delayed by at least 15 minutes
Sell:$3.59
Buy:$3.60
Change:$0.16 (4.51%)
Market closed |
Prices delayed by at least 15 minutes
Sell:$3.59
Buy:$3.60
Change:$0.16 (4.51%)
Market closed |
Prices delayed by at least 15 minutes

Company Information

About this company

Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Key people

Jerome Benedict Durso
Chairman of the Board
Vipin K. Garg
President, Chief Executive Officer, Director
Gregory L. Weaver
Chief Financial Officer
M. Scot Roberts
Chief Scientific Officer
M. Scott Harris
Chief Medical Officer
Raymond M. Jordt
Chief Business Officer
John M. Gill
Independent Director
Philip L. Hodges
Independent Director
Diane K. Jorkasky
Independent Director
Teri L. Lawver
Independent Director
Wayne F. Pisano
Independent Director
Click to see more

Key facts

  • EPIC
    ALT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US02155H2004
  • Market cap
    $299.19m
  • Employees
    59
  • Shares in issue
    88.26m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.